Successful clearance of hepatitis C virus with pegylated interferon α-2a and ribavirin in an etanercept-treated patient with psoriatic arthritis, hepatitis B virus coinfection and latent tuberculosis

Annals of the Rheumatic Diseases

Volumn 70, Issue 7, 2011, Pages 1343-1344

  Mederacke, Ingmar ^a   Witte, Torsten ^a   Wedemeyer, Heiner ^a   Meyer Olson, Dirk ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; HLA B27 ANTIGEN; ISONIAZID; LAMIVUDINE; PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS DNA; VIRUS RNA;

ADULT; CASE REPORT; DRUG WITHDRAWAL; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LATENT TUBERCULOSIS; LETTER; MALE; MIXED INFECTION; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RELAPSE; REMISSION; TREATMENT OUTCOME; TUBERCULIN TEST; VIRAL CLEARANCE;

ADULT; ANTIVIRAL AGENTS; ARTHRITIS, PSORIATIC; DRUG THERAPY, COMBINATION; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; INTERFERON ALFA-2A; LATENT TUBERCULOSIS; MALE; POLYETHYLENE GLYCOLS; RECEPTORS, TUMOR NECROSIS FACTOR; RIBAVIRIN;

EID: 79957630539     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2010.139824     Document Type: Letter

References (10)

1. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661-2.
2. Cansu DU, Kalifoglu T, Korkmaz C. Short-term course of chronic hepatitis B and C under treatment with etanercept associated with different disease modifying antirheumatic drugs without antiviral prophylaxis. J Rheumatol 2008;35:421-4. (Pubitemid 351374414)
3. Vassilopoulos D, Apostolopoulou A, Hadziyannis E, et al. Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Ann Rheum Dis 2010;69:1352-5.
4. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75.
5. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227-42.
6. Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335-74.
7. Potthoff A, Manns MP, Wedemeyer H. Treatment of HBV/HCV coinfection. Expert Opin Pharmacother 2010;11:919-28.
8. Zein NN. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol 2005;42:315-22. (Pubitemid 40254244)
9. Niewold TB, Gibofsky A. Concomitant interferon-alpha therapy and tumor necrosis factor alpha inhibition for rheumatoid arthritis and hepatitis C. Arthritis Rheum 2006;54:2335-7. (Pubitemid 44051096)
10. Behnam SE, Hindiyeh R, Fife DJ, et al. Etanercept as prophylactic psoriatic therapy before interferon-alpha and ribavirin treatment for active hepatitis C infection. Clin Exp Dermatol 2010;35:397-8.